UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2007
BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-15360
Oregon | | 93-1099680 |
(State or other jurisdiction of
incorporation or organization) | | (I.R.S. Employer
Identification No.) |
20245 SW 95th Avenue
Tualatin, Oregon | | 97062 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (503) 692-8001
Former name or former address if changed since last report:
No Change
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
BIOJECT MEDICAL TECHNOLOGIES INC.
FORM 8-K
INDEX
Item | | Description | | Page |
| | | | |
Item 5.02 | | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | | 2 |
| | | | |
Signatures | | | | 3 |
1
Item 5.02 Departure of Directors and Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation of Arrangements of Certain Officers
(e) On December 20, 2007, Mr. Jerald Cobbs was granted 93,750 shares of Bioject Medical Technologies Inc.’s (“Bioject”) common stock under Bioject’s 1992 Restated Stock Incentive Plan as compensation for his services as interim Chief Executive Officer for a three-month period from July to October 2007. The closing price for Bioject’s common stock on December 20, 2007 was $0.60. Accordingly, the fair value of the stock grant was $56,250.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 21, 2007 | BIOJECT MEDICAL TECHNOLOGIES INC. |
| (Registrant) |
| |
| /s/ CHRISTINE M. FARRELL |
| Christine M. Farrell |
| Vice President of Finance |
| (Principal Financial and Accounting Officer) |
3
